GNRH1 and endometriosis: Linzagolix (75–100–200 mg daily), the newest compound of GnRH antagonists, has been investigated for 24-week treatment in a phase IIb trial [196] and in the extension study up to 52 weeks [197], which showed promising therapeutic effects on pain symptoms in women with endometriosis.